Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | JAK3 | P52333 | 1/20 | 0.41 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 5/20 | 0.38 |
| ▸ | GSK3A | P49840 | 2/20 | 0.37 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | CDK2 | P24941 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 3/20 | 0.35 |
| ▸ | MAPK12 | P53778 | 3/20 | 0.35 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2932651 | 0.88 | MAPK14 (0.40) | MGLLMAPK14GSK3AGSK3BCDK2 | |
| SCHEMBL2924940 | 0.85 | GSK3A (0.41) | MGLLMAPK14GSK3AGSK3BCDK2 | |
| SCHEMBL2932325 | 0.84 | VCP (0.47) | MGLLMAPK14GSK3AGSK3BCDK2 | |
| SCHEMBL1384726 | 0.74 | TGFBR1 (0.41) | CYP3A4MAPK14CDK2MAPK1MAPK13 | |
| SCHEMBL1385324 | 0.73 | TOP2A (0.43) | MAPK14GSK3AGSK3BCDK2HDAC1 | |
| SCHEMBL7556151 | 0.73 | MAPK13 (0.47) | EGFRCYP3A4BRAFJAK3MAPK10 | |
| SCHEMBL2932352 | 0.72 | GSK3B (0.40) | JAK3KCNH2MAPK14GSK3AGSK3B | |
| SCHEMBL7001627 | 0.72 | MAPK13 (0.50) | EGFRCYP3A4BRAFJAK3MAPK10 | |
| SCHEMBL6170828 | 0.69 | MAPK13 (0.49) | EGFRCYP3A4BRAFJAK3MAPK10 | |
| SCHEMBL7670671 | 0.69 | TRPC3 (0.43) | EGFRCYP3A4BRAFJAK3MAPK10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8536194-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2013-09-17 | — | — | US | disclosed |
| EP-1611131-B1 | PYRAZOLOPYRIDINE DERIVATES | PALAU PHARMA SA (ES) | 2010-09-15 | — | — | EP | disclosed |
| US-20090286983-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-11-19 | — | — | US | disclosed |
| US-20090005377-A1 | Pyrazolopyridine Derivates | PALAU PHARMA, S.A. (ES) | 2009-01-01 | — | — | US | disclosed |
| US-7468376-B2 | Pyrazolopyridine derivates | PALAU PHARMA, S.A. (ES) | 2008-12-23 | — | — | US | disclosed |
| US-20060167040-A1 | Pyrazolopyridine derivates | J. URIACH Y COMPANIA S.A. (ES) | 2006-07-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167040-A1 | Pyrazolopyridine derivates | MAPK1, MAP4K2, MAP4K3 | EGFR 3479/4885CYP3A4 502/4885BRAF 41/4885 |
| US-20090286983-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | EGFR 3439/4885CYP3A4 1093/4885BRAF 43/4885 |
| US-20090005377-A1 | Pyrazolopyridine Derivates | MAPK1, MAPK4, MAP4K2 | EGFR 3439/4885CYP3A4 1093/4885BRAF 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.